The Board of Starpharma announced the appointment of Dr. Jeff Davies as an independent non-executive director, effective 1 April 2022. Dr. Davies is a former CSL executive, with over 35 years of biopharmaceutical experience, holding senior executive roles at CSL, including Executive Vice President & General Manager at CSL for the Asia-Pacific region, and Global Head of Plasma Product Research and Development at CSL-Behring, Switzerland.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.115 AUD | -4.17% | -8.00% | -32.35% |
Apr. 08 | Starpharma, Medicxi Co-Found Petalion Therapeutics; Shares Surge 16% | MT |
Mar. 18 | Starpharma Holdings Limited(ASX:SPL) dropped from S&P/ASX Emerging Companies Index | CI |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-32.35% | 33.04M | |
+31.37% | 595B | |
-2.60% | 367B | |
+20.83% | 334B | |
+5.69% | 289B | |
+14.83% | 239B | |
+9.93% | 211B | |
-6.95% | 203B | |
+10.77% | 171B | |
+0.10% | 163B |
- Stock Market
- Equities
- SPL Stock
- News Starpharma Holdings Limited
- Starpharma Holdings Limited Appoints Jeff Davies as Non-Executive Director, Effective 1 April 2022